Author has a cautious position in IonQ, acknowledging it feels like a mistake rather than a true conviction play. While IonQ has respectable revenue and good leadership, real-world use cases remain distant, and the position is vulnerable if AI hype deflates—though a potential partnership with NVIDIA could provide upside.

Investor seeking conviction trade between IONQ (quantum computing) and CRSP (gene editing) after receiving bonus/windfall. Both companies discussed as strong conviction cases with inquiry about near-term bullish catalysts and relative merits.

Three AI infrastructure plays positioned to benefit from the shift from chip bottlenecks to power/compute capacity constraints: Constellation Energy (CEG) as the stable nuclear baseload anchor with existing reactors feeding hyperscaler demand, Oklo (OKLO) as a beaten-down small modular reactor pure-play with Meta/Nvidia partnerships, and IonQ (IONQ) as a high-risk quantum computing play with government backing. Key risks include execution delays on new reactor builds, pre-revenue burn rates at OKLO/IONQ, and regulatory/permitting uncertainty.

User observes someone celebrating their birthday by adding positions to their portfolio, identifying holdings in IONQ, CRWD, BUD, META, and MNST. The post is casual speculation about portfolio composition with no fundamental analysis or investment thesis presented.

INFQ is positioned as the best quantum computing play due to its fresh IPO status, small market cap enabling asymmetric moves, imminent $2 billion government grant catalyst, and differentiated neutral-atom technology. Key risks include minimal revenue (~$10M/quarter), significant net losses ($30.26M in Q1 2026), and binary event dependency on federal funding approval.